Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease: A preclinical primate study

Hideyuki Yoshida, Isao Date, Tetsuro Shingo, Kenjiro Fujiwara, Kazuki Kobayashi, Yasuyuki Miyoshi, Takashi Ohmoto

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Object. The PC12 cells are well known for their ability to secrete dopamine and levodopa. In multiple animal models encapsulated PC12 cells have been shown to ameliorate parkinsonian symptoms when transplanted into the striatum; this technique is expected to be effective clinically as well. The present study was performed using nonhuman primates to ensure that the transplantation of encapsulated PC12 cells is likely to be both safe and effective in human clinical trials. Methods. Unencapsulated or encapsulated PC12 cells were implanted into the brains of Japanese monkeys (Macaca fuscata). Histological and immunocytochemical analyses were performed 1, 2, 4, and 8 weeks posttransplantation on the unencapsulated cells and 2, 4, and 8 weeks after transplantation on the encapsulated cells. The survival of the PC12 cells inside the capsule was determined by measuring the amounts of dopamine and levodopa released from the capsules after removal from the striatum. Magnetic resonance imaging was performed in both unencapsulated and encapsulated PC12 cell-grafted groups. Due to the immunological reaction of the host brain no unencapsulated PC12 cells remained in the grafted area 8 weeks after transplantation. On the contrary, encapsulated PC12 cells retrieved from the host brain continued to release dopamine and levodopa even 8 weeks after implantation. The host's reaction to the PC12-loaded capsule was much weaker than that to the unencapsulated PC12 cells. Conclusions. These results suggest that the transplantation of encapsulated PC12 cells could be a safe and effective treatment modality for Parkinson disease in human patients.

Original languageEnglish
Pages (from-to)874-881
Number of pages8
JournalJournal of Neurosurgery
Volume98
Issue number4
Publication statusPublished - Apr 1 2003

Fingerprint

PC12 Cells
Primates
Capsules
Parkinson Disease
Dopamine
Transplantation
Levodopa
Macaca
Brain
Animal Models
Magnetic Resonance Imaging
Clinical Trials

Keywords

  • Macaca fuscata
  • Neural transplantation
  • Nonhuman primate
  • Parkinson disease
  • PC12 cell

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease : A preclinical primate study. / Yoshida, Hideyuki; Date, Isao; Shingo, Tetsuro; Fujiwara, Kenjiro; Kobayashi, Kazuki; Miyoshi, Yasuyuki; Ohmoto, Takashi.

In: Journal of Neurosurgery, Vol. 98, No. 4, 01.04.2003, p. 874-881.

Research output: Contribution to journalArticle

Yoshida, Hideyuki ; Date, Isao ; Shingo, Tetsuro ; Fujiwara, Kenjiro ; Kobayashi, Kazuki ; Miyoshi, Yasuyuki ; Ohmoto, Takashi. / Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease : A preclinical primate study. In: Journal of Neurosurgery. 2003 ; Vol. 98, No. 4. pp. 874-881.
@article{42031da002b043f38bfc5b1b1d49402b,
title = "Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease: A preclinical primate study",
abstract = "Object. The PC12 cells are well known for their ability to secrete dopamine and levodopa. In multiple animal models encapsulated PC12 cells have been shown to ameliorate parkinsonian symptoms when transplanted into the striatum; this technique is expected to be effective clinically as well. The present study was performed using nonhuman primates to ensure that the transplantation of encapsulated PC12 cells is likely to be both safe and effective in human clinical trials. Methods. Unencapsulated or encapsulated PC12 cells were implanted into the brains of Japanese monkeys (Macaca fuscata). Histological and immunocytochemical analyses were performed 1, 2, 4, and 8 weeks posttransplantation on the unencapsulated cells and 2, 4, and 8 weeks after transplantation on the encapsulated cells. The survival of the PC12 cells inside the capsule was determined by measuring the amounts of dopamine and levodopa released from the capsules after removal from the striatum. Magnetic resonance imaging was performed in both unencapsulated and encapsulated PC12 cell-grafted groups. Due to the immunological reaction of the host brain no unencapsulated PC12 cells remained in the grafted area 8 weeks after transplantation. On the contrary, encapsulated PC12 cells retrieved from the host brain continued to release dopamine and levodopa even 8 weeks after implantation. The host's reaction to the PC12-loaded capsule was much weaker than that to the unencapsulated PC12 cells. Conclusions. These results suggest that the transplantation of encapsulated PC12 cells could be a safe and effective treatment modality for Parkinson disease in human patients.",
keywords = "Macaca fuscata, Neural transplantation, Nonhuman primate, Parkinson disease, PC12 cell",
author = "Hideyuki Yoshida and Isao Date and Tetsuro Shingo and Kenjiro Fujiwara and Kazuki Kobayashi and Yasuyuki Miyoshi and Takashi Ohmoto",
year = "2003",
month = "4",
day = "1",
language = "English",
volume = "98",
pages = "874--881",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "4",

}

TY - JOUR

T1 - Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease

T2 - A preclinical primate study

AU - Yoshida, Hideyuki

AU - Date, Isao

AU - Shingo, Tetsuro

AU - Fujiwara, Kenjiro

AU - Kobayashi, Kazuki

AU - Miyoshi, Yasuyuki

AU - Ohmoto, Takashi

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Object. The PC12 cells are well known for their ability to secrete dopamine and levodopa. In multiple animal models encapsulated PC12 cells have been shown to ameliorate parkinsonian symptoms when transplanted into the striatum; this technique is expected to be effective clinically as well. The present study was performed using nonhuman primates to ensure that the transplantation of encapsulated PC12 cells is likely to be both safe and effective in human clinical trials. Methods. Unencapsulated or encapsulated PC12 cells were implanted into the brains of Japanese monkeys (Macaca fuscata). Histological and immunocytochemical analyses were performed 1, 2, 4, and 8 weeks posttransplantation on the unencapsulated cells and 2, 4, and 8 weeks after transplantation on the encapsulated cells. The survival of the PC12 cells inside the capsule was determined by measuring the amounts of dopamine and levodopa released from the capsules after removal from the striatum. Magnetic resonance imaging was performed in both unencapsulated and encapsulated PC12 cell-grafted groups. Due to the immunological reaction of the host brain no unencapsulated PC12 cells remained in the grafted area 8 weeks after transplantation. On the contrary, encapsulated PC12 cells retrieved from the host brain continued to release dopamine and levodopa even 8 weeks after implantation. The host's reaction to the PC12-loaded capsule was much weaker than that to the unencapsulated PC12 cells. Conclusions. These results suggest that the transplantation of encapsulated PC12 cells could be a safe and effective treatment modality for Parkinson disease in human patients.

AB - Object. The PC12 cells are well known for their ability to secrete dopamine and levodopa. In multiple animal models encapsulated PC12 cells have been shown to ameliorate parkinsonian symptoms when transplanted into the striatum; this technique is expected to be effective clinically as well. The present study was performed using nonhuman primates to ensure that the transplantation of encapsulated PC12 cells is likely to be both safe and effective in human clinical trials. Methods. Unencapsulated or encapsulated PC12 cells were implanted into the brains of Japanese monkeys (Macaca fuscata). Histological and immunocytochemical analyses were performed 1, 2, 4, and 8 weeks posttransplantation on the unencapsulated cells and 2, 4, and 8 weeks after transplantation on the encapsulated cells. The survival of the PC12 cells inside the capsule was determined by measuring the amounts of dopamine and levodopa released from the capsules after removal from the striatum. Magnetic resonance imaging was performed in both unencapsulated and encapsulated PC12 cell-grafted groups. Due to the immunological reaction of the host brain no unencapsulated PC12 cells remained in the grafted area 8 weeks after transplantation. On the contrary, encapsulated PC12 cells retrieved from the host brain continued to release dopamine and levodopa even 8 weeks after implantation. The host's reaction to the PC12-loaded capsule was much weaker than that to the unencapsulated PC12 cells. Conclusions. These results suggest that the transplantation of encapsulated PC12 cells could be a safe and effective treatment modality for Parkinson disease in human patients.

KW - Macaca fuscata

KW - Neural transplantation

KW - Nonhuman primate

KW - Parkinson disease

KW - PC12 cell

UR - http://www.scopus.com/inward/record.url?scp=0037385053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037385053&partnerID=8YFLogxK

M3 - Article

C2 - 12691415

AN - SCOPUS:0037385053

VL - 98

SP - 874

EP - 881

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 4

ER -